There have been not many reports on the result of intralesional excision for giant cell tumors (GCTs) of the great trochanter and femoral neck because of its rarity. The authors present the case of a 35-year-old female patient managed with intralesional curettage and filling the defect with autologous bone graft from iliac crest. An appoint of three doses of Denosumab was done postoperatively. The article discusses the clinical aspects and surgical treatment, and the benefits of Denosumab. This report aimed to demonstrate the possibility to perform curetage for giant cell tumor of the hip even the recommandation for this location is wide resection and endoprothesis fixation.
Introduction
Giant cell tumors (GCT) are relatively rare (5% to 10% of bone tumors). They are benign in 90% of cases and more often sit on the limbs (90%) with an almost constant epiphyso-metaphyseal localization: knee (60%), proximal end of the humerus (15%), distal ends of the radius (10%) %) or tibia (10%). These are tumors of young adults (75% of cases between 20 and 40 years) [1] . Curettage and filling the osseous defect is the reference treatment for uncomplicated cases, but is followed by local recurrences in 20% to 40% of cases [2] [3] [4] . Moreover, in terms of localization to the proximal femur, few results are reported due to its rarity. There are only a few "case reports" and short series [5] 
Observation
Mrs. SM, a 35-year-old patient consulted in the department for pain and dodge lameness of the left hip evolving for six months around. There was no notion of trauma. There was no specific pathological history. On examination, there was a pain awakened to the palpation supported by the greater trochanter and to the mobilization of the hip. The mobility of the joint was normal. The general condition was well preserved and the biological balance showed no abnormality.
The standard X-ray of the frontal pelvis and the profile hip showed a circumscribed osteolytic image of the greater trochanter and of the femoral neck ( Figure 1 ). At six months postoperative, the patient was asymptomatic. A good fusion of the bone graft was noted (Figure 4 ).
At two years of age, the patient was still asymptomatic and the radiographs showed no recurrence ( Figure 5 ).
Discussion
The treatment of GCT is primarily surgical. These are tumors that can be locally aggressive and sometimes give distant metastases although they are considered histologically as benign. The goal of the treatment is to eliminate the entire . Moreover most surgeons are reluctant to perform a prosthetic reconstruction in a young adult. Despite these reservations, some authors advocate this method in the proximal femur [15] . Whatever the method used, recurrences are frequent, occurring between a few months and five years, in proportions of 20% to 40% according to the series [16] [17] [18] [19] . In 15% of cases, it is malignant degeneration [20] [21] [22] . The recurrence factors explored in the literature are age, sex, tumor site, histological grade, pathological fracture and type of surgery. For most authors there is no statistically significant relationship between these factors and the reccurence.
[22] [23] . As for the type of surgery (curettage or resection), only the functional result differs and is better in the case of conservative treatment [24] . The majority of authors therefore consider curettage to be the first-line method of treating most cases of GCT, even in the event of recurrence [3] [29] . In the Norwegian protocol [26] the administration of Denosumab in postoperative care was performed by subcutaneous injection every 4 weeks for a period of six months.
The location of GCT at the proximal end of the femur is quite rare. In our precarious situation, total hip arthroplasty remains a challenge, especially if it is a reconstruction with special prostheses. So we had only the option of curettagefill that we realized. To strengthen this treatment, we have added Denosumab. But given the high cost of the product we administered only 3 injections at 1 month intervals. At 2 years postoperative, we have not yet observed a recurrence. This seems to testify to the efficacy of Denosumab, even if administered for a limited time. However, regular monitoring should be continued for a few more years because recurrences at fifteen or even twenty years have been described [20] [30].
Conclusions
The treatment of the circumscribed GCT is resolutely surgical and the curettagefilling is the method of choice. The appearance of Denosumab has improved the prognosis. The result we have reached suggests at least for the moment that the duration of administration may be shortened, in particular when financial accessibility is limited.
